Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212


Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.

Ceppi P, Rapa I, Lo Iacono M, Righi L, Giorcelli J, Pautasso M, Billè A, Ardissone F, Papotti M, Scagliotti GV.

Int J Cancer. 2012 Apr 15;130(8):1777-86. doi: 10.1002/ijc.26188. Epub 2011 Aug 5.


Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.

Wilson PM, LaBonte MJ, Lenz HJ, Mack PC, Ladner RD.

Mol Cancer Ther. 2012 Mar;11(3):616-28. doi: 10.1158/1535-7163.MCT-11-0781. Epub 2011 Dec 15.


Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ.

Mol Pharmacol. 2008 Apr;73(4):1290-300. doi: 10.1124/mol.107.042382. Epub 2008 Jan 10.


Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.

Ceppi P, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV.

Mol Cancer Ther. 2009 Nov;8(11):3066-74. doi: 10.1158/1535-7163.MCT-09-0151. Epub 2009 Oct 27.


Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.

Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, Trisciuoglio D.

Mol Cancer. 2014 Oct 9;13:230. doi: 10.1186/1476-4598-13-230.


Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.

Monica V, Lo Iacono M, Bracco E, Busso S, Di Blasio L, Primo L, Peracino B, Papotti M, Scagliotti G.

Oncotarget. 2016 Nov 22;7(47):76577-76589. doi: 10.18632/oncotarget.10428.


Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.

Lung Cancer. 2011 Oct;74(1):132-8. doi: 10.1016/j.lungcan.2011.01.024. Epub 2011 Mar 1.


Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.

Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT, Ko JL.

J Thorac Oncol. 2010 Aug;5(8):1143-51. doi: 10.1097/JTO.0b013e3181e0b954.


Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.

Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K.

Br J Cancer. 2011 May 10;104(10):1594-601. doi: 10.1038/bjc.2011.129. Epub 2011 Apr 12.


Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ.

Br J Cancer. 2008 Sep 2;99(5):750-9. doi: 10.1038/sj.bjc.6604566. Epub 2008 Aug 19.


The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.

Kanou T, Oneyama C, Kawahara K, Okimura A, Ohta M, Ikeda N, Shintani Y, Okumura M, Okada M.

Mol Cancer Res. 2011 Jan;9(1):103-14. doi: 10.1158/1541-7786.MCR-10-0340. Epub 2010 Dec 14.


Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.

Markova B, Hähnel PS, Kasper S, Herbertz S, Schuler M, Breitenbuecher F.

J Cancer Res Clin Oncol. 2012 Apr;138(4):545-54. doi: 10.1007/s00432-011-1123-9. Epub 2011 Dec 28.


Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.

Tung CL, Chiu HC, Jian YJ, Jian YT, Chen CY, Syu JJ, Wo TY, Huang YJ, Tseng SC, Lin YW.

Exp Cell Res. 2014 Apr 1;322(2):345-54. doi: 10.1016/j.yexcr.2014.02.002. Epub 2014 Feb 12.


Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.


Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.


Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.

Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review.


Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.

Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F.

Chemotherapy. 2008;54(3):166-75. doi: 10.1159/000140360. Epub 2008 Jun 18.


Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.

Liao KS, Wei CL, Chen JC, Zheng HY, Chen WC, Wu CH, Wang TJ, Peng YS, Chang PY, Lin YW.

Regul Toxicol Pharmacol. 2016 Nov;81:353-361. doi: 10.1016/j.yrtph.2016.09.031. Epub 2016 Sep 28.


Supplemental Content

Support Center